Split-Release Gamma-Hydroxybutyrate for Once-Nightly PK Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing modified release formulations of gamma-hydroxybutyrate suffer from low bioavailability and inconvenience due to the need for multiple doses and high sodium intake, failing to approximate the pharmacokinetic profile of immediate release sodium oxybate administered twice nightly.
Innovation Solution
A modified release formulation of gamma-hydroxybutyrate that rapidly releases half of its dose in 0.1N hydrochloric acid and the other half in phosphate buffer pH 6.8, achieving bioavailability comparable to twice-nightly immediate release sodium oxybate, with a combination of immediate and modified release portions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If modified release formulations of gamma-hydroxybutyrate are used, then convenience is improved by reducing dosing frequency, but bioavailability deteriorates and pharmacokinetic profile deviates from immediate release formulations
Solution Approach 1:
The formulation is divided into two distinct portions: an immediate release portion containing 10-50% of the total gamma-hydroxybutyrate and a modified release portion containing 50-90% of the total gamma-hydroxybutyrate. This segmentation allows the immediate release portion to provide rapid initial absorption for quick therapeutic effect, while the modified release portion provides sustained release for extended duration, together achieving both convenience and reliable bioavailability
Solution Approach 2:
The patent modifies the release characteristics by changing the physical and chemical parameters of the formulation components. The modified release portion uses specific excipients and coating materials that control the dissolution rate and release profile of gamma-hydroxybutyrate, transforming it from immediate release to controlled modified release while maintaining overall bioavailability through the combined portions
2Reliability
If immediate release sodium oxybate is administered twice nightly, then pharmacokinetic efficacy is maintained, but convenience deteriorates due to multiple dosing requirements
Solution Approach 1:
The patent merges two separate dosing events into a single combined formulation administered once nightly. The immediate release portion mimics the first dose's rapid absorption, while the modified release portion extends drug availability to cover the full night, effectively combining the pharmacokinetic effects of two separate doses into one convenient administration
Solution Approach 2:
The modified release portion ensures continuous release of gamma-hydroxybutyrate throughout the night, maintaining therapeutic levels without interruption. This continuous action eliminates the need for a second dose while ensuring uninterrupted pharmacokinetic efficacy throughout the treatment period
3Reliability
If high doses of sodium oxybate are administered, then therapeutic efficacy is improved, but harmful factors increase due to high sodium intake
Solution Approach 1:
The patent changes the chemical form of gamma-hydroxybutyrate from sodium salt to other pharmaceutically acceptable salts or free acid forms. This parameter change maintains the therapeutic efficacy of gamma-hydroxybutyrate while significantly reducing or eliminating the sodium content, thereby reducing harmful effects associated with high sodium intake
Data Source
AI summary
Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.